Curriculum Vitae

Personal information

Roland Froetschl

Work experience

1. Employer: University Hospital Charite
   - Start date: 061994
   - End date: 021999
   - Position: PostDoc in research, Project leader Gene Technology
   - Activities: research in drug metabolism, pharmacogenetics and transcriptional activation of metabolising systems in mammalians, pharmacogenetic polymorphisms in major drug metabolizing enzymes, construction of genetically modified cell cultures for investigation of transcriptional activation
   - Country: Germany
2. Employer: Stefan Morsch Stiftung
   - Start date: 021999
   - End date: 071999
   - Position: scientific employee
   - Activities: HLA diagnostics in blood samples for bone marrow donors database
   - Country: Germany
3. Employer: own business
   - Start date: 101999
   - End date: 022001
   - Position: independent scientist
   - Activities: research in expression of drug metabolism enzymes and transcriptomic signatures in mammalian cells for the Federal Institute for Drugs and Medical Devices
   - Country: Germany
4. Employer: Federal Institute for Drugs and Medical Devices
   - Start date: 032001
   - End date:
   - Position: preclinical assessor and senior scientist
   - Activities: Risk assessment of genotoxic and carcinogenic risk of drugs, research group leader in toxicogenomics and biomarker research
   - Country: Germany

Education and training

1. Subject: University Stuttgart
   - Start date: 101983
   - End date: 121988
   - Qualification: Diploma (equivalent to Master of Science) in Biology
   - Organisation: biochemistry, cell biology, molecular biology
   - Country: Germany
2. Subject: German Type Culture Collection, Prof. Dr Guenter Adam / University Stuttgart
   - Start date: 011989
   - End date: 021995
   - Qualification: PhD in Biology
   - Organisation: gene technology, transformation of bacterial and eucaryotic cells, molecular defense mechanisms to viral pathogens
   - Country: Germany
3. Subject: Society of Toxicology in the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) & Federation of European Toxicologists & European Societies of Toxicology (EUROTOX)
   - Start date: 012010
   - End date: 012016
   - Qualification: Fachtoxikologe (Board Certified Toxicologist) DGPT, European Registered Toxicologist ERT
   - Organisation: General Toxicology, Human Toxicology, Environmental Toxicology, Toxicokinetics, Metabolism, Chemical Mutagenesis and Carcinogenesis,
   - Country: Germany

Additional information

Publications

Frötschl, R., Schönfelder, M., Mundry, K._W. & Adam, G. (1989). Examination of Plant Virus_inhibiting Proteins from Plants in in vitro Systems. "Proceedings of the Braunschweig Symposium on Applied Plant Molecular Biology", Galling, G. Ed., TU Braunschweig, Braunschweig, FRG. 317_322.
Frötschl, R., Schönfelder, M. and Adam, G., 1990: Studies on the Fun¬ction of Antiviral Plant Proteins. Archives of Phytopathology and Plant Protection, 26, 4, 319_328.
Griegel, S., Hong, C., Frötschl, R., Hülser, D.F., Greger, V., Horsthemke, B. and Rajewsky, M.F., 1990: Newly Establis¬hed Human Retinoblastoma Cell Lines Exhibit an "Immortalized" but not an Invasive Phenotype in Vitro. International Journal of Cancer, 46, 125_132.
Schönfelder, M., Janott, U., Frötschl, R., Mundry, K.W. and Adam, G., 1992: Purification of Antiviral Proteins with Ribo¬some_Inactivating Properties from Plants. Zeitschrift für Naturforschung, 47c, 731_738.
Agranovsky, A.A., Koonin, E.V., Boyko, V.P., Maiss, E., Frötschl, R., Lunina, N.A. and Atabekov, J.G., 1994: Beet Yellows Closterovirus: Complete Genome Structure and Identification of a Leader Papain_like Thiol Protease.

Virology, 198, 1, 311_324.
Frötschl, R., 1995: Untersuchungen zur Funktion, Lokalisierung und Klonierung ribosomeninaktivierender Proteine aus Pflanzen. R. Frötschl (editor), Papierflieger, Clausthal_Zellerfeld, Germany, ISBN 3_930697_83_1.
Frötschl, R., Kleeberg, U., Hildebrandt, A.G., Roots, I. and Bröckmöller, J., 1996: PCR based construction of a competitor target for quantitative RT_PCR application of cytochrome P450 1A1 mRNA. Analytical Biochemistry, 242, 280_282.
Roots, I., Brockmöller, J., Bräutigam, K., Bauer, S., Frötschl, R., Johne, A., Rost, K.L., Mai, I. 1998. Analyse von Arzneimittelinteraktionen bei der Helicobacter_pylori_Eradikationstherapie: pharmakokinetische, enzymspezifische und genetische Daten. In Ott, T., Hefendehl, F._W., und Grosdanoff, P. (Eds): Arzneimittel und Medizinprodukte, Bewertung _ Verfahren _ Perspektiven. Bundesinsitut für Arzneimittel und Medizinprodukte, Berlin, ISBN 3_931542_01_7, pp 129_142.
Frötschl, R. Chichmonov, L., Kleeberg, U., Hildebrandt, A.G., Roots, I., and Brockmöller, J. 1998: Prediction of Ah_receptor mediated enzyme induction of drugs and chemicals by mRNA quantification. Chemical Research in Toxicology, 11(12), 1447_1452.
Kleeberg, U., Frötschl, R., Krusekopf, S., Brockmöller, J., Roots, I., Ruckpaul, K., and Hildebrandt, A.G. 1999: Induction of CYP1A by various benzimidazoles and ist significance in administrative drug regulation. Drug Metabolism Reviews, 31(2), 381_392.
Kleeberg, U., Frötschl, R. 2001. Pharmakogenetik und Polymorphismen: Chance für eine individuelle Pharmakotherapie? Der Klinikarzt, 201, 43_48 Gaikovitch, E.A., Cascorbi, I., Mrozikiewicz, P.M., Brockmoller, J., Frötschl, R., Kopke, K., Gerloff, T., Chernov, J.N., and Roots, I. 2003: Polymorphisms of drug_metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P_glycoprotein in a Russian population. European Journal of Clinical Pharmacology, 59(4), 303_312.
Frötschl, R., Weickardt, S., Staszewski, S., Kaufmann, G., and Kasper, P. 2005: Effects of Chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutation Research, 575(1_2), 47_60.
Susanne Brendler_Schwaab, Peter Kasper, Pierre Aeby, Bernd Epe, Roland Frötschl, Elmar Gocke, Cynthia Hertel, Stephan Kirchner, Manfred Liebsch, Krista Meurer, Ulla Plappert_Helbig, Elisabeth Schmidt 2006. New aspects of photogenotoxicity testing: Prevalidation of the photo_micronucleus test and the photo_comet assay. Proceedings of the British Toxicology Society & the United Kingdom Environmental Mutagen Society Joint Congress. University of Warwick, Warwick, UK, 19th to 22nd March, 2006. Toxicology 2006 Vol. 226(1):24_25.
Frötschl, R., Kasper P. 2008. Microarrays in drug development: regulatory perspective. In: Bosio A, Gerstmayer B. editors. Microarrays in Inflammation. Basel Boston Berlin: Birkhäuser Verlag, 2008; 199_209.
Kasper P., Frötschl R. 2009. Kontrolle von Verunreinigungen bei der Arzneimittelherstellung. Pharm. Ind. 71(7), 1135_1140.
Darrell R. Abernethy, Anthony J. DeStefano, Todd L. Cecil, Kahkashan Zaidi, Roger L. Williams, and the USP Metal Impurities Advisory Panel (Nancy Lewen (Chair), Timothy L. Shelbourn (Vice Chair), Charles Barton, Courtney M. Callis, Steven J. Dentali, Anna M Fan, Roland Frotschl, Assad Kazeminy, Richard Ko, Gregory C. Turk, Robert Wiens, Government Liaisons□: Renee Blosser, FDA, Mamata De, FDA, Bruce A. Fowler, CDC, John F. Kauffman, FDA, Jill C. Merrill, FDA) 2010. Metal Impurities in Food and Drugs Pharmaceutical Research 27 (5):750_755.
Krämer E., Frötschl R., 2010. Identifizierung von Biomarkern zur Vorhersage genotoxischer Wirkmechanismen. Bulletin zur Arzneimittelsicherheit 4:15_17.
Krämer E, Schütz E, Frötschl R: Site specific phosphorylation of p53 may depend on phosphorylation of p38 defferently activated by substances with different genotoxic mode of action.2011 Mutagenesis 26(5):717_718 p89.
Pfuhler S., Fellows M., van Benthem J., Corvi R., Curren R., Dearfield K., Fowler P., Frötschl R., Elhajouji A., Le Hégarat L., Kasamatsu T., Kojima H., Ouédraogo G., Scott A., Speit G. 2011. In vitro genotoxicity test approaches with better predictivity: Summary of an IWGT workshop. Mutation Research, 723(2):1001_107.
Frötschl, R., 2013. 3.4.2 Case 2: TXG_Data to clarify relevance of neoplastic effects in rodent life time bioassays: a case study. In "Omics and Risk Assessment Science". 25_26 February 2013, Malaga. ECETOC Workshop Report No. 25, Brussels 2013, ISSN_2078_7200_25 print, ISSN_2078_7219_25 online, p 23_25.
Mader RM, Foerster S, Sarin N, Michaelis M, Cinatl J Jr, Kloft C, Fröhlich H, Engel F, Kalayda GV, Jäger W, Frötschl R, Jaehde U, Ritter CA (2014). NSCLC cells adapted to EGFR inhibition accumulate EGFR interacting proteins and down_regulate microRNA related to epithelial_mesenchymal transition. Int J Clin Pharmacol Ther. 52(1):92_4.
Kalayda GV, Michaelis M, Cinatl J Jr, Mader RM, Fröhlich H, Sarin N, Melin J, Engel F, Jäger W, Frötschl R, Jaehde U, Kloft C, Ritter CA (2014). A systems pharmacology approach to improve drug therapy in NSCLC: establishing a CESAR network. Int J Clin Pharmacol Ther. 52(1):89_91 Gollapudi, B.B, Lynch, A.M., Heflich, R.H., Dertinger, S.D., Dobrovolsky, V.N., Froetschl, R., Horibata, K., Kenyon, M.O., Kimoto, T., Lovell, D.P., Stankowski Jr., L.F., White, P.A., Witt, K.L., Tanir, J.Y., (2014) The in vivo Pig_a assay: A report of the International Workshop On Genotoxicity Testing (IWGT) Workgroup, Mutation Research/Genetic Toxicology and Environmental Mutagenesis, Available online 26 September 2014, ISSN 1383_5718, http://dx.doi.org/10.1016/j.mrgentox.2014.09.007.
MacGregor, J.T., Frötschl, R., White, P.A., Crump, K.S., Eastmond, D.A., Fukushima, S., Guérard, M., Hayashi, M., Soeteman_Hernandez, L., Kasamatsu, T., Levy, D.D., Morita, T., Müller, L., Schoeny, R., Schuler, M.J. Thybaud, V., Johnson, G.E., (2014) IWGT report on quantitative approaches to genotoxicity risk assessment I. Methods and metrics for defining exposure–response relationships and points of departure (PoDs). Mutation Research/Genetic Toxicology and Environmental Mutagenesis, Available online 13 October 2014, ISSN 1383_5718, http://dx.doi.org/10.1016/j.mrgentox.2014.09.011.
MacGregor, J.T., Frötschl, R., White, P.A., Crump, K.S., Eastmond, D.A., Fukushima, S., Guérard, M., Hayashi, M., Soeteman_Hernandez, L., Johnson, G.E., Kasamatsu, T., Levy, D.D., Morita, T., Müller, L., Schoeny, R., Schuler, M.J. Thybaud, V., (2014) IWGT Report on Quantitative Approaches to Genotoxicity Risk Assessment II. Use of Point_of_Departure (PoD) metrics in defining acceptable exposure limits and assessing human risk, Mutation Research/Genetic Toxicology and Environmental Mutagenesis, Available online 27 October 2014, ISSN 1383_5718, http://dx.doi.org/10.1016/j.mrgentox.2014.10.008.
Guérard, M., Baum, M., Bitsch, A., Eisenbrand, G., Elhajouji, A., Epe, B., abermeyer, M., Kaina, B., Martus, HJ., Pfuhler, S., Schmitz, C., Sutter, A., Thomas, A.D., Ziemann, C., and Frötschl, R., (2014) Assessment of mechanisms driving non_linear dose_response relationships in genotoxicity testing. Mut. Res. Rev. https://dx.doi:10.1016/j.mrrev.2014.11.001.
Frötschl R. (2015). Experiences with the in vivo and in vitro comet assay in regulatory testing. Mutagenesis 30(1):51_57.
Frötschl R. Müller, L. (2015) ICH M7 Leitlinie zur Bewertung und Kontrolle von DNA_reaktiven (mutagenen) Verunreinigungen in Arzneimitteln zur Begrenzung des karzinogenen Risikos. Pharm. Ind. 77(9):1320_1325.
Haas, B., Weber_Lassalle, K., Frötschl, R, Eckstein, N. (2016). Is sunitinib a Narrow Therapeutic Index Drug? _ A systematic review and in vitro toxicology_analysis of Sunitinib vs. Imatinib in cells from different tissues. Regulatory Toxicology and Pharmacology 77:25_34.
Vasquez, M.Z., Frötschl, R. (2016). The In Vivo Comet Assay. Chapter 10 in "Genetic Toxicology Testing: A Laboratory Manual". p 345_382, Ray Proudlock Ed. Elsevier Academic Press 2016 ISBN 978_0_12_800764_8.
Sarin, N., Engel, F., Kalayda, G.V, Frötschl, R., Cinatl jr., J., Rothweiler, F., Michaelis, M., Fröhlich, H., and Jaehde, U. (2016). Knowledge_based approach to identify key determinants of cisplatin sensitivity. Int J Clin Pharmacol Ther. 54():xx_xx DOI 10.5414/ CPXCES15EA04.
Klaus V, Bastek H, Damme K, Collins LB, Frötschl R, Benda N, Lutter D, Ellinger_Ziegelbauer H, Swenberg JA, Dietrich DR, Stemmer K. (2017) Time_matched analysis of DNA adduct formation and early gene expression as predictive tool for renal carcinogenesis in methylazoxymethanol acetate treated Eker rats. Arch Toxicol. 2017 Mar 27. doi: 10.1007/s00204_017_1953_6.
Sarin, N., Engel, F., Kalayda, G.V., Mannewitz, M., Cinatl, J. Jr., Rothweiler, F., Michaelis. M., Saafan, H., Ritter, C.A., Jaehde, U., Frötschl, R. (2017) Cisplatin resistance in non_small cell lung cancer cells is associated with an abrogation of cisplatin_induced G2/M cell cycle arrest. PLoS ONE 12(7): e0181081. https://doi.org/10.1371/journal.pone.0181081.
Li, H_H., Chen, R., Hyduke D.R., Williams, A., Frötschl, R., Ellinger_Ziegelbauer, H., O'Lone, R., Yauk, C.L., Aubrecht, J., and Fornace, A.L. Jr. (2017) Development and validation of a high_throughput transcriptomic biomarker to address 21st century genetic toxicology needs PNAS 2017 ; published ahead of print December 4, 2017, doi:10.1073/pnas.1714109114.

Sarin, N., Engel, F., Rothweiler, F., Cinatl Jr, J., Michaelis, M., Frötschl, R., Fröhlich, H., and Kalayda, G.V., (2018) Key Players of Cisplatin Resistance: Towards a Systems Pharmacology Approach. Int J Mol Sci 2018, 19(3), 767; doi: 10.3390/ijms19030767.
Haas, B., Klinger, V., Keksel, C., Bonigut, V., Kiefer, D., Caspers, J., Walther, J., Wos_Maganga, M., Weickhardt, S., Röhn, G., Timmer, M., Frötschl, R., Eckstein, N. (2018). Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs. Cancer Cell Int. 2018 May 4;18:69. doi: 10.1186/s12935_018_0565_4.
Igl BW, Bitsch A, Bringezu F, Chang S, Dammann M, Frötschl R, Harm V, Kellner R, Krzykalla V, Lott J, Nern M, Pfuhler S, Queisser N, Schulz M, Sutter A, Vaas L, Vonk R, Zellner D, Ziemann C (2019) The rat bone marrow micronucleus test: Statistical considerations on historical negative control data. Regulatory Toxicology and Pharmacology 102:13_22.
Li HH, Yauk C, Chen R, Hyduke DR, Williams A, Frötschl R, Ellinger_Ziegelbauer HC, Pettit S, Aubrecht J, Fornace Jr. AJ (2019). TGx_DDI, a transcriptomic biomarker for genotoxicity hazard assessment of pharmaceuticals and environmental chemicals. Frontiers in Big Data 2019, 08 October 2019, Vol 2, doi: 10.3389/fdata.2019.00036.
Sasaki JC, Allemang A, Bryce SM, Custer L, Dearfield KL, Dietz Y, Elhajouji A, Escobar PA, Fornace AJ Jr, Froetschl R, Galloway S, Hemmann U, Hendriks G, Li HH, Luijten M, Ouedraogo G, Peel L, Pfuhler S, Roberts DJ, Thybaud V, van Benthem J, Yauk CL, Schuler M. Application of the adverse outcome pathway framework to genotoxic modes of action. Environ Mol Mutagen. 2019 Oct 11. doi: 10.1002/em.22339.
Lynch AM, Eastmond D, Elhajouji A, Froetschl R, Kirsch_Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M, Tweats D. (2019). Targets and mechanisms of chemically induced aneuploidy. Part 1 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases. Mutat. Res. 847:403025 doi: 10.1016/j.mrgentox.2019.02.006.
Pacchierotti F, Masumura K, Eastmond DA, Elhajouji A, Froetschl R, Kirsch_Volders M, Lynch A, Schuler M, Tweats D, Marchetti F. (2019). Chemically induced aneuploidy in germ cells. Part II of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases. Mutat Res. 2019 Dec;848:403023. doi: 10.1016/j.mrgentox.2019.02.004.
Tweats D, Eastmond DA, Lynch AM, Elhajouji A, Froetschl R, Kirsch_Volders M, Marchetti F, Masumura K, Pacchierotti F, Schuler M. (2019). Role of aneuploidy in the carcinogenic process: Part 3 of the report of the 2017 IWGT workgroup on assessing the risk of aneugens for carcinogenesis and hereditary diseases. Mutat. Res. 847:403032. doi: 10.1016/j.mrgentox.2019.03.005.
Yauk CL, Harrill AH, Ellinger_Ziegelbauer H, van der Laan JW, Moggs J, Froetschl R, Sistare F, Pettit S (2019) A cross_sector call to improve carcinogenicity risk assessment through use of genomic methodologies. Regul Toxicol Pharmacol. 2019 Nov 11:104526. doi: 10.1016/j.yrtph.2019.104526.
Martus HJ, Froetschl R, Gollapudi B, Honma M, Marchetti F, Pfuhler S, Schoeny R, Uno Y, Yauk C, Kirkland DJ.(2020) Summary of major conclusions from the 7th International Workshop on Genotoxicity Testing (IWGT), Tokyo, Japan. Mutat Res. 2020 Apr;852:503134. doi: 10.1016/j.mrgentox.2020.503134. Epub 2020 Jan 13. PMID: 32265038.
Frötschl R, Haas B, Weise M, (2020). Umgang mit Arzneimittelrisiken am Beispiel von Nitrosaminen – Teil 2: toxikologische Bewertung. Bulletin zur Arzneimittelsicherheit 2020;3:11_16.
Chorley BN, Atabakhsh E, Doran G, Gautier JC, Ellinger_Ziegelbauer H, Jackson D, Sharapova T, Yuen PST, Church RJ, Couttet P, Froetschl R, McDuffie J, Martinez V, Pande P, Peel L, Rafferty C, Simutis FJ, Harrill AH. Methodological considerations for measuring biofluid_based microRNA biomarkers. Crit Rev Toxicol. 2021 Mar;51(3):264_282. doi: 10.1080/10408444.2021.1907530. Epub 2021 May 26. PMID: 34038674.
Kaina, B., Thomas, A., Visser, H., Hengstler, J., Frötschl, R. (2021), Do Carcinogens Have a Threshold Dose? The Pros and Cons. Regulatory Toxicology, Springer_Nature Germany 2021, https://doi.org/10.1007/978_3_642_36206_4_55_2.
Gomm W, Röthlein C, Schüssel K, Brückner G, Schröder H, Heß S, Frötschl R, Broich K, Haenisch B: N_nitrosodimethylamine–contaminated valsartan and the risk of cancer—a longitudinal cohort study based on German health insurance data. Dtsch Arztebl Int 2021; 118: 357–62. DOI: 10.3238/arztebl.m2021.0129.
Ruepp R, Frötschl R, Bream R, Filancia M, Girard T, Spinei A, Weise M, Whomsley R. The EU Response to the Presence of Nitrosamine Impurities in Medicines. Front Med (Lausanne). 2021 Nov 19;8:782536. doi: 10.3389/fmed.2021.782536. PMID: 34869504; PMCID: PMC8641785.
Nicolette J, Luijten M, Sasaki JC, Custer L, Embry M, Froetschl R, Johnson G, Ouedraogo G, Settivari R, Thybaud V, Dearfield KL. Utility of a next_generation framework for assessment of genomic damage: A case study using the pharmaceutical drug candidate etoposide. Environ Mol Mutagen. 2021 Nov;62(9):512_525. doi: 10.1002/em.22467. Epub 2021 Nov 22. PMID: 34775645.
Corton JC, Mitchell CA, Auerbach S, Bushel P, Ellinger_Ziegelbauer H, Escobar PA, Froetschl R, Harrill AH, Johnson K, Klaunig JE, Pandiri AR, Podtelezhnikov AA, Rager JE, Tanis KQ, van der Laan JW, Vespa A, Yauk CL, Pettit SD, Sistare FD. A Collaborative Initiative to Establish Genomic Biomarkers for Assessing Tumorigenic Potential to Reduce Reliance on Conventional Rodent Carcinogenicity Studies. Toxicol Sci. 2022 Jun 28;188(1):4_16. doi: 10.1093/toxsci/kfac041. PMID: 35404422; PMCID: PMC9238304.
Beal M, Audebert M, Barton_Maclaren T, Battaion H, Bemis J, Cao X, Chen C, Dertinger S, Froetschl R; Guo X, Johnson G, Hendriks G, Khoury L, Long A, Pfuhler S, Settivari R, Wickramasuriya S, White P. Quantitative in vitro to in vivo Extrapolation (IVIVE) of Genotoxicity Data Provides Protective Estimates of in vivo Dose. Environ Mol Mutagen. 2022_11_21 DOI: 10.22541/au.166906427.70641401/v1.
Lynch AM, Zanoni TB, Salk JJ, Martincorena I, Young RR, Kucab J, Valentine CC, Yauk C, Escobar PA, Witt KL, Frötschl R, Reed SH, Ashford A. Next Generation Sequencing Workshop at the Royal Society of Medicine (London, May 2022): How genomics is on the path to modernizing Genetic Toxicology. Mutagenesis. 2023 Jun 10:gead012. doi: 10.1093/mutage/gead012. Epub ahead of print. PMID: 37300447.
Kruhlak NL, Schmidt M, Froetschl R, Graber S, Haas B, Horne I, Horne S, King ST, Koval IA, Kumaran G, Langenkamp A, McGovern TJ, Peryea T, Sanh A, Siqueira Ferreira A, van Aerts L, Vespa A, Whomsley R. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA). Regul Toxicol Pharmacol. 2024 Jun;150:105640. doi: 10.1016/j.yrtph.2024.105640. Epub 2024 May 14. PMID: 38754805.
Meier MJ, Caiment F, Corton JC, Frötschl R, Fujita Y, Jennen D, Mezencev R, Yauk C. Outcome of IWGT workshop on transcriptomic biomarkers for genotoxicity: Key considerations for bioinformatics. Environ Mol Mutagen. 2024 Dec 16. doi: 10.1002/em.22644. Epub ahead of print. PMID: 39676751.
Froetschl R, Corton JC, Li H, Aubrecht J, Auerbach SS, Caiment F, Doktorova TY, Fujita Y, Jennen D, Koyama N, Meier MJ, Mezencev R, Recio L, Suzuki T, Yauk CL. Consensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity. Environ Mol Mutagen. 2025 Jan 5. doi: 10.1002/em.22645. Epub ahead of print. PMID: 39757731
Li HH, Aubrecht J, Doktorova TY, Jennen D, Corton JC, Froetschl R, Mezencev R, Yauk CL. Review of transcriptomic biomarkers that predict *in vitro* genotoxicity in human cell lines. Environ Mol Mutagen. 2025 March 04 doi:10.1002/em.70004 Epub ahead of print

Projects

ICH M7 "Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk" EU Expert in the Expert Working Group, EU Topic Lead; ICH M7 Sub-group "Risk Assessment and Control of Nitrosamine Impurities" EU Expert in the Expert Working Group, EU Topic Lead; ICH Q3D " Guideline for Elemental Impurities" EU Expert in the Expert Working Group, Current Rapporteur; ICH Q3C "Guideline for Residual Solvents" EU Expert in the Expert Working Group, Current Rapporteur; HESI eSTAR Global research project "Qualification of genomic biomarkers for providing mechanistic context to positve findings in the in vitro chromosome damage assays"; HESI eSTAR Global research project "Carcinogenomics"; HESI GTTC Quantitative Analysis Workgroup; HESI GTTC Mode of Action Workgroup; HESI GTTC MGRA Nitrosamines Workgroup; Consortial partner in EMA funded project MutaMind contract EMA/2020/46/L1.02

Memberships	Member of GUM (Environmental Mutation Research Society, Germany), Member of European Environmental Mutagens and Genomics Society (EEMGS) since 2014 Member of Excecutive Board of EEMGS, Member of DGPT (German Society for Experimental and Clinical Pharmacology and Toxicology), Member of HESI (Health and Environmental Science Institute) Board of Trustees
Other Relevant Information	